NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Mahzi Therapeutics

Mahzi Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://mahzi.com/

Last Round

Grant

Mar 27, 2026

Total Funding Raised

$47.79M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Mahzi Therapeutics is a biotechnology company that develops precision therapies for rare genetic neurodevelopmental disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyantisense oligonucleotidesASOprecision medicineneurodevelopmental disordersAAV9rare diseasebiotechgene replacement therapyclinical-stage biotechdrug discoveryorphan druggenetic medicineclinical trialsbiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mahzi Therapeutics Comparables

Compare Mahzi Therapeutics with similar companies based on industry and business-model similarity.

Mahzi Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Neurogene
79%
Capsida Biotherapeutics
77%
Encoded Therapeutics
76%

Mahzi Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 27, 2026
GrantJan 30, 2025
GrantJun 27, 2024
GrantNov 29, 2022
Early FundingOct 7, 2021
Seed
Dec 1, 2020

Key People

Founding team and executive leadership

Yael Weiss

Chief Executive Officer

Executive Team

Aaron Olsen

Chief Financial Officer

Executive Team

Mahzi Therapeutics Investors

Notable investors and investment history

Mahzi Therapeutics investors
InvestorRounds
Droia VenturesEarly Funding
HealthCapEarly Funding
ArrowMark PartnersEarly Funding
HBM Healthcare InvestmentsEarly Funding
California Institute for Regenerative MedicineGrant
VenrockEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 27, 2026

    $8M grant from California Institute for Regenerative Medicine.

Mahzi Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mahzi Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mahzi Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range21
Year Founded2021
Last FundingMar 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.